Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
This article was originally published in The Pink Sheet Daily
Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.
You may also be interested in...
Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?
The antibody specialist said no to Biogen Idec in December and found a better offer of nearly $10 more a share.
Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.